IM-250
Appearance
![]() | |
Names | |
---|---|
IUPAC name
(S)-2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
| |
Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
Properties | |
C20H19F2N3O2S2 | |
Molar mass | 435.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
IM-250 is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.[3]
Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.[4]
See also
[edit]References
[edit]- ^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.
- ^ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.
- ^ "Small molecule fights active and latent herpes infections in rodents".
- ^ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.